FDA Approves Novel Prostate Cancer “Vaccine”
The treatment, which works by turning the body’s immune system against invading cancer cells, is called Provenge and is manufactured by Seattle biotech firm Dendreon
Read more on Time Magazine
FDA Approves Novel Prostate Cancer “Vaccine”
Heart Drugs Show Promise for Fighting Colon Cancer
Jenny Felth, Joachim Gullbo, and colleagues note that cardiac glycosides are a family of naturally-derived drugs used to treat congestive heart failure and abnormal heart rhythms. Scientists have suspected for some time, based on previous research, that these heart drugs may have promise for fighting many different types of cancer. Despite this, knowledge on effects in colon cancer or combination effects with other anti-cancer drugs is lacking. But scientists know little about their potential anticancer effects and have not tested these substances against colon cancer.
As part of a larger study to screen and identify natural substances with activity against colon cancer, the scientists picked several cardiac glycosides for further study. They tested five of these heart drugs against laboratory cultures of human colon cancer cells and found that they were all effective, to varying degrees, at killing the cancer cells.
» Read more: Heart Drugs Show Promise for Fighting Colon Cancer
Related posts
Terramed Alliance News Younger Breast Cancer Patients Have Greater Chance Of Recurrence, Especially After Certain Treatments
Previous studies have shown that younger breast cancer patients consistently have poorer outcomes than patients who develop the disease later in life, which can translate into lower rates of overall survival. While the reason for this is not known, it is suggested that breast cancer in younger patients is more biologically aggressive.
Researchers from the University of Texas M.D. Anderson Cancer Center in Houston sought to determine which form of breast cancer treatment – breast-conserving therapy, mastectomy alone or mastectomy with adjuvant radiation – better benefits younger women with either Stage I or Stage II breast cancer.